Table 2.
Baseline / pre-dose characteristics of the study population.
| Characteristic | All patients (n = 27) |
|---|---|
| Age (years) | 58 (16) |
| Sex (n (%)) | |
| Male | 6 (22) |
| Female | 21 (78) |
| Race (n (%)) | |
| Caucasian | 27 (100) |
| BMI (kg/m2) | 27 (7) |
| SBP (screening) (mmHg) | 120 (20) |
| DBP (screening) (mmHg) | 70 (10) |
| Patients with SBP < 100 mmHg immediately prior to dosing (n) | 7 |
| Concomitant medications | |
| ERA (n) | 25 |
| Bosentan | 17 |
| Ambrisentan | 7 |
| Macitentan | 1 |
| PDE5i (n) | 22 |
| Sildenafil | 17 |
| Tadalafil | 5 |
| Anti-thrombotic agents (n) | 27 |
| Phenprocoumon | 16 |
| Rivaroxaban | 3 |
| Acetylsalicylic acid | 3 |
| Warfarin | 2 |
| Apixaban | 1 |
| Enoxaparin | 1 |
| Heparin | 1 |
Data are mean (standard deviation) unless otherwise indicated.
BMI, body mass index; ERA, endothelin receptor antagonist; PDE5i, phosphodiesterase-5 inhibitor.